Q1 2024 Earnings Forecast for Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Issued By HC Wainwright

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at HC Wainwright dropped their Q1 2024 earnings per share (EPS) estimates for shares of Acrivon Therapeutics in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.89) per share for the quarter, down from their previous forecast of ($0.88). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($3.61) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.57) EPS, Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($2.63) EPS, FY2025 earnings at ($3.18) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($1.65) EPS and FY2028 earnings at ($1.04) EPS.

Other research analysts also recently issued reports about the company. LADENBURG THALM/SH SH lowered their target price on Acrivon Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, April 5th. BMO Capital Markets reiterated an “outperform” rating and set a $18.00 target price on shares of Acrivon Therapeutics in a research report on Monday, April 1st. Finally, JMP Securities reiterated a “market outperform” rating and set a $14.00 target price on shares of Acrivon Therapeutics in a research report on Monday, April 1st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.14.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $9.99 on Friday. The company has a market capitalization of $226.17 million, a P/E ratio of -3.66 and a beta of 1.94. Acrivon Therapeutics has a one year low of $3.19 and a one year high of $14.30. The stock has a 50 day moving average price of $5.48 and a 200-day moving average price of $5.30.

Institutional Trading of Acrivon Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACRV. Marshall Wace LLP purchased a new stake in Acrivon Therapeutics during the 4th quarter valued at $14,092,000. BlackRock Inc. purchased a new stake in Acrivon Therapeutics during the 1st quarter valued at $6,018,000. Geode Capital Management LLC purchased a new stake in Acrivon Therapeutics during the 1st quarter valued at $2,226,000. State Street Corp purchased a new stake in Acrivon Therapeutics during the 1st quarter valued at $1,083,000. Finally, Vanguard Group Inc. raised its holdings in Acrivon Therapeutics by 16.2% during the 3rd quarter. Vanguard Group Inc. now owns 468,407 shares of the company’s stock valued at $4,478,000 after buying an additional 65,132 shares during the period. Hedge funds and other institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.